Septerna, Inc. filed a Form S-1 registration statement for an initial public offering on 2024-10-02. It has amended it 2 times. It filed its final prospectus on 2024-10-25, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock has been approved for listing on the Nasdaq Global Market under the symbol of SEPN.From the 424B4 filed 2024-10-25
Shares offered
We are offering 16,000,000 shares of our common stock.From the 424B4 filed 2024-10-25
Offering price
The initial public offering price per share is $18.00.From the 424B4 filed 2024-10-25
Use of proceeds
We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents, and marketable securities, as follows: approximately $117 million to advance the continued development of SEP-786, our lead product candidate from our PTH1R program through completion of a Phase 2 clinical trial in hypoparathyroidism patients and initiation of a Phase 3 clinical trial, and additional molecules targeting PTH1R; approximately $37 million to advance the development of SEP-631 through completion of a Phase 1 clinical trial and initiation of Phase 2 clinical studies, and additional small molecules within our MRGPRX2 program; approximately $57 million for other…From the 424B4 filed 2024-10-25
Revenue
Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023.From the S-1/A filed 2024-10-24
Net loss or income
Our net loss was $27.7 million for the year ended December 31, 2022 and net income was $4.2 million for the year ended December 31, 2023.From the S-1/A filed 2024-10-24
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-10-02 | Registration statement filed | S-1 |
| 2024-10-21 | Registration statement amended | S-1/A |
| 2024-10-24 | Registration statement amended | S-1/A |
| 2024-10-25 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Septerna, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.